PTRA test to be used in Kidney Transplant Tx Study
Verici Dx plc
(“Verici Dx” or the “Company”)
Verici Dx PTRA tests to be used in Kidney Transplant Therapy Clinical Study
The use of RNA signature tests reflects the growing role of molecular diagnostics in clinical development, providing new insights into patient response and supporting more personalized approaches to transplant medicine
Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces an order with Asahi Kasei Therapeutics, Inc for a Phase 2 clinical trial evaluating pegrizeprument (VEL-101), an investigational maintenance immunosuppressive therapy being developed for the prevention of acute rejection in solid organ transplant recipients.
As part of its order of tests and further services, Verici Dx will perform blood-based biomarker testing, including the Pre-Transplant Risk Assessment (PTRA) assay, as exploratory research tools as part of the clinical trial. The molecular data generated will help evaluate biomarker signatures associated with immune pathways activity, metabolic dysregulation, and homeostasis associated with transplant outcomes in patients receiving pegrizeprument.
PTRA is a blood-based next generation sequencing (NGS) gene expression with algorithm assay. The PTRA assay measures the pre-transplant expression of immune-response genes associated with early acute rejection.
Simon Tremblay, Senior Director, Clinical Development, Asahi Kasei Therapeutics, said:
"As we advance the clinical development of pegrizeprument, we are committed to building a deeper understanding of how patients respond to novel immunosuppressive therapies. Working with Verici Dx allows us to incorporate advanced molecular biomarker analyses into our clinical programme, generating additional scientific insights that may help inform the future of precision medicine in kidney transplantation."
Sara Barrington, CEO of Verici Dx, said:
"Clinical trials represent an important opportunity to better understand the biological mechanisms underlying transplant success and rejection. By incorporating advanced molecular diagnostics into therapeutic development and clinical research, we can generate valuable insights that may ultimately help personalize post-transplant care. We are excited to support Asahi Kasei Therapeutics on this important study and look forward to contributing our expertise in transplant biomarkers."
Verici Dx plc
Sara Barrington, CEO
Via Walbrook PR
Julian Baines, Chairman
Singer Capital Markets
(Nominated Adviser, Joint Broker & Joint Bookrunner)Tel: +44 (0)20 7496 3000
Russell Cook / Anastassiya Eley / Harry Littlewood
Oberon Capital
(Joint Broker & Joint Bookrunner)Tel: +44 (0)20 3179 0500
Mike Seabrook / Heena Karani
Walbrook PR
(Media & Investor Relations)Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com
Alice Woodings / Rachel Broad
Mob: +44 (0)7407 804 654 / +44 (0)7747 515 393
About Verici Dx plc www.vericidx.com
Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines transcriptomic analysis with proprietary tests with underlying technology based upon artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence.
Operating at the intersection of laboratory and data science, Verici Dx develops complex models that the Company believes answer the clinical questions that matter most with clarity and precision. All commercially available tests are built to rigorous scientific standards, validated across inclusive, and real-world patient populations to ensure clinical relevance and reliability. Verici Dx's lead product, Tutivia™, is a post-kidney transplant test focused on early detection of acute rejection.
The company is UK headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit https://vericidx.com and follow us on LinkedIn.
in Cardiff for the UK, and in Franklin, Tennessee for the U.S.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDMSCFEDESFEMSEDS
